A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
After the completion of local regulatory approvals, Aytu anticipates exporting to Medomie both of its novel, orally disintegrating, extended-release tablets for the treatment of ADHDENGLEWOOD, CO and GIVATAYIM, ISRAEL / July 31, 2023 / Aytu BioPharma, Inc. (the...
Company Expects a Six-Month Review of the Prior Approval Supplement Submission by the U.S. Food & Drug Administration Which, if Approved, Enables the Transfer of Cotempla Production to Contract ManufacturerUpon Completion of Manufacturing Transfer of Adzenys...
ENGLEWOOD, CO / June 14, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced Joshua Disbrow, Aytu's Chief Executive Officer, will participate in a...
Abhinav Jain of Nantahala Capital Management, LLC Joins the Company's Board of Directors Upon ClosingPotential for Additional $7 Million in Event of Exercise of Common Warrants in FullExtends Interest Only Period on Avenue Capital Term Loan Through January 2025...
Abhinav Jain of Nantahala Capital Management, LLC Joins the Company's Board of Directors Upon ClosingPotential for Additional $7 Million in Event of Exercise of Common Warrants in FullExtends Interest Only Period on Avenue Capital Term Loan Through January 2025...
Total prescriptions increased 32% compared to Q3 2022 to highest level in Company historyCompany to host conference call today at 4:30pm ETENGLEWOOD, CO / May 11, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and...
ENGLEWOOD, CO / May 4, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report financial...
ENGLEWOOD, CO / May 1, 2023 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, entered into an...
U.S. Food & Drug Administration Approval of Prior Approval Supplement Enables Transfer of Adzenys Production to Contract Manufacturer in 2023Upon Completion of Manufacturing Transfer of Adzenys XR-ODT and Cotempla XR-ODT, Company Expects to Improve ADHD Product...
Second Consecutive Quarter of Positive Adjusted EBITDAQuarterly Net Revenue of $26.3 Million Driven by 23% Growth in Rx SegmentCompany to Host Conference Call Today at 5:00pm ETENGLEWOOD, CO / February 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu")...